Irwin Naturals Files Q2 2022 Financials

August 30, 2022 MJ Shareholders

Ryan Allway August 30th, 2022 News, Top News Rapid Execution on Cannabis Licensing and Ketamine ClinicRollup Strategy to Accelerate Future Growth LOS ANGELES, Aug....

Ryan Allway

August 30th, 2022

News, Top News

Rapid Execution on Cannabis Licensing and Ketamine Clinic
Rollup Strategy to Accelerate Future Growth

LOS ANGELES, Aug. 30, 2022 (GLOBE NEWSWIRE) — Irwin Naturals Inc. (CSE: IWIN) (OTC: IWINF) (FRA: 97X) (“Irwin” or the “Company”) announced the Company filed results for its second quarter of fiscal 2022, the period ended June 30, 2022 on www.sedar.com.

Philippe Faraut, CFO, stated, “While supply chain issues, reduced inventory at our customers and product transitions resulted in an 18% decrease in revenues, we maintained profitability. Additionally, as we continue to execute on our cannabis licensing and ketamine clinic rollup strategy, we will be adding new revenue streams to our results in the quarters to come. Following a bump in sales once the nation emerged from the most severe Covid related restrictions, we believe that our mass market (nutraceutical) business, we are now tracking back to normal sales patterns, which we believe will result in secular growth in the coming quarters.”

Mr. Faraut continued, “We maintain a healthy balance sheet, have very limited debt and have access to considerable working capital through our credit line and other instruments to invest in accelerated growth through our Emergence clinics and cannabis business lines. With acquisitions resulting in 11 clinics announced and completed, we anticipate seeing considerable growth coming from our Emergence business in the coming quarters, further supported by the rollout of our licensing deals, which now sees us in four states and in Canada.”

Financial Summary

	Three months ended									Six months ended
(in thousands)	June 30,				$			%		June 30,				$			%
Combined Statement of Profit		2022		2021	Change			Change			2022		2021	Change			Change
Non-CBD operating revenue	$	20,125	$	24,100	$	(3,975	)	-16.5	%	$	40,860	$	45,435	$	(4,575	)	-10.1	%
CBD operating revenue		1,684		2,493		(809	)	-32.5	%		3,543		5,293		(1,750	)	-33.1	%
Total Operating Revenue		21,809		26,593		(4,784	)	-18.0	%		44,403		50,728		(6,325	)	-12.5	%

Gross Profit		9,559		12,106		(2,547	)	-21.0	%		20,605		23,853		(3,248	)	-13.6	%

Income from Operations		505		3,135		(2,630	)	-83.9	%		3,031		6,938		(3,907	)	-56.3	%

Net Profit		111		2,977		(2,866	)	-96.3	%		1,692		6,692		(5,000	)	-74.7	%

	As of		As of		$			%
Statement of Financial Position		June 30, 2022		Dec 31, 2021	Change			Change
Total assets		63,785		47,219		16,566		35.1	%
Total liabilities		34,031		24,103		9,928		41.2	%

Klee Irwin, CEO, commented, “The current proliferation of scientific research into the efficacy of psychedelics assisted mental health treatments has sorted two effects. On the one hand, treating physicians are taking notice of the remarkable results this line of treatment can accomplish, which is driving adoption amongst physicians and other mental health workers. On the demand side, we are seeing a rapidly accelerating destigmatization of psychedelics. Both are drivers that will continue to grow the market and with our rapidly expanding clinics chain, we are exceptionally well positioned to capitalize on this growth.”

Mr. Irwin continued, “While we saw similar patterns with cannabis, we believe that the strong science behind these treatments, with buy-in from both medical professionals and patients, will show an accelerated adoption curve. The one element that was missing was a trusted brand. With the Irwin Naturals brand recognized by over 100 million North Americans, there is now a well-known and trusted provider in the space. This, we believe, will drive additional patients our way to drive a marked acceleration of revenue and profitability growth.”

Financial Highlights

The 18.0% decline in overall operating revenues were due largely to supply issues in the CBD segment, related to a fire at a key supplier. The decline in sales is believed to be temporary as production of CBD products has restarted at the Company’s manufacturer. Other factors impacting sales related to order timing and the loss of distribution of certain non-CBD mass market products.
Income from operations in Q2 2022 came in at $0.5 million, as compared to $3.1 million for the same period in the prior year. The reduction in income was driven primarily by the aforementioned decrease in business volume and startup costs related to Emergence by Irwin Naturals (ketamine clinics) and Irwin Naturals Cannabis (intellectual property licensing to the cannabis industry).
The overall decrease in business volume paired with startup costs related to the Company’s initiatives in cannabis and the aforementioned startup costs, resulted in a decrease in EBITDA¹ to $0.7 million.

	Three months ended										Six months ended
(in thousands)	June 30,					$			%		June 30,					$			%
		2022			2021	Change			Change			2022			2021	Change			Change
Net Profit	$	111		$	2,977	$	(2,866	)	-96.3	%	$	1,692		$	6,692	$	(5,000	)	-74.7	%
Interest Expense		111			29		82		282.8	%		360			57		303		531.6	%
Income Tax Expense		283			129		154		119.4	%		979			189		790		418.0	%
Depreciation and Amortization		426			353		73		20.7	%		831			707		124		17.5	%
EBITDA	$	931		$	3,488	$	(2,557	)	-73.3	%	$	3,862		$	7,645	$	(3,783	)	-49.5	%

Other Income		(263	)		–		(263	)	100.0	%		(263	)		–		(263	)	0.0	%
Adjusted EBITDA	$	668		$	3,488	$	(2,820	)	-80.8	%	$	3,599		$	7,645	$	(4,046	)	-52.9	%

¹EBITDA is a non IFRS metric that management believes provides a metric for rapid analysis of the underlying strength of the business. A reconciliation from IFRS to EBITDA is provided in the accompanying table above and at the end of this release.

Cash Flows from Operating Activities: Cash provided by operating came in at $5.9 million and $10.5 million for the six months ended June 30, 2022 and 2021, respectively. The decrease in operating cash flows is primarily due to lower operating revenue and temporary unfavorability to working capital led by the timing of payments to the Company’s primary product manufacturer and non-cash share capital issuance.
Positive cash flow from operations, combined with a largely undrawn line of credit, provides the Company with the financial resources to drive continued execution of its strategy.

Operational Highlights & Subsequent Events

Irwin Naturals is executing on an aggressive expansion strategy into the high-growth cannabis and psychedelics sectors. The Company intends to leverage its household name brand status to drive an aggressive rollup of mental health clinics (the Company is focused on ketamine clinics, as this is currently the only FDA-approved and/or regulated psychedelic substance). Furthermore, the Company has begun executing on its brand licensing strategy throughout the US. To date, the Company has announced or completed the acquisition of 11 clinics, as well as the signing of five brand licensing deals that will see Irwin Naturals products enhanced with THC be offered in California, Colorado, New Mexico, Ohio and Canada.

State	Clinic Acquisitions
Florida	Ketamine Health Centers (5 clinics)
Iowa	Midwest Ketafusion
New Hampshire	New England Ketamine
Mexico	Ketamine Health Centers
Vermont	Preventive Medicine
Georgia	Invictus Clinics (2 clinics)

State	Brand Licenses
California	The Hive
Colorado	Larsen Group II
Ohio	BeneLeaves
New Mexico	Assurance Laboratories
Canada	Entourage

Business highlights and subsequent events

About Irwin Naturals

Irwin Naturals has been a household name and best-in-class nutraceutical company since 1994. It is now leveraging its brand into both the cannabis and psychedelic sectors. On a mission to heal the world with plant medicine, Irwin has operated profitably for over 27 years*. The growing portfolio of products is available in more than 100,000 retail doors across North America, where 80% of households know the Irwin Naturals brand**. In 2018, the Company first leveraged its brand to expand into the cannabis industry by launching hemp-based CBD products into the mass market. The Company is now leveraging its famous halo of brand trust to become, perhaps, the first household name brand to offer THC-based products. Its rapidly growing national chain of psychedelic mental health clinics is called Irwin Naturals Emergence.

*Under several corporate structures, Klee Irwin has operated the Irwin brand profitably since 1994, as measured by EBITDA adjusted for extraordinary costs.

**Based on a formal Company survey with a sample size of 500 randomly selected adults.

For investor-related information about the Company, please visit ir.irwinnaturals.com/

To contact the Company’s Investor Relations department, please call toll-free at (800) 883-4851 or send an email to [email protected].

“Klee Irwin”
________________________________
Klee Irwin
Chief Executive Officer
T: 310-306-3636
[email protected]

IR Information

Press Contact

Irwin Naturals Investor Relations
Cassandra Bassanetti-Drumm
T: 310-306-3636
[email protected]

Regulatory Overview

The following is a brief summary of regulatory matters concerning ketamine in the United States (“US”). Under the Controlled Substances Act (21 U.S.C. § 811) (the “CSA”), ketamine is currently a Schedule III drug as well as being listed under the associated Narcotic Control Regulations, and psilocybin is currently a Schedule I drug.

Most US States have enacted Controlled Substances Acts (“State CSAs”) which regulate the possession, use, sale, distribution, and manufacture of specified drugs or categories of drugs and establish penalties for State CSA violations and form the basis for much state and local drug laws enforcement activity. State CSAs have either adopted drug schedules identical or similar to the federal CSA schedules or, in some instances, have incorporated the federal scheduling mechanism. Among other requirements, some US States have established a prescription drug monitoring or review programs collect information about prescription and dispensing of controlled substances for the purposes of monitoring, analysis and education.

In the United States, facilities holding or administering controlled substances must be registered with the US Drug Enforcement Agency (“DEA“) to perform this activity. As such, medical professionals and/or the clinics in which they operate, as applicable, are also required to have a DEA license to obtain and administer ketamine (a “DEA License“). While ketamine is a controlled substance in the United States, it is approved for general anesthetic induction under the US Food, Drug, and Cosmetic Act. Once a drug is approved for use, physicians may prescribe that drug for uses that are not described in the product’s labelling or that differ from those tested by the manufacturer and approved by the Food and Drug Administration (the “FDA“). Licensed medical practitioners may prescribe ketamine legally in Canada or the United States where they believe it will be an effective treatment in their professional judgment.

Please see Irwin’s filing statement on its SEDAR profile for more information on the regulatory environment and regulations surrounding the US THC industry.

Forward-Looking Information

This news release contains certain forward-looking statements that reflect the current views and/or expectations of management of the Company with respect to performance, business and future events. Forward-looking statements can often be identified by words such as “may”, “will”, “would”, “could”, “should”, “believes”, “estimates”, “projects”, “potential”, “expects”, “plans”, “intends”, “anticipates”, “targeted”, “continues”, “forecasts”, “designed”, “goal”, or the negative of those words or other similar or comparable words. Forward-looking statements are based on the then-current expectations, beliefs, assumptions, estimates and forecasts about the business and the industry and markets in which the Company operates. The Company does not undertake any obligation to release publicly any revisions for updating any voluntary forward-looking statements, except as required by applicable securities law.

Neither the CSE nor its Market Regulator (as that term is defined in policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

SOURCE: Irwin Naturals Inc.

EBITDA and Adjusted EBITDA – Reconciliation

The Company defines EBITDA and Adjusted EBITDA as per the table below. It should be noted that these performance measures are not defined under IFRS and may not be comparable to similar measures used by other entities. The Company believes that these measures are useful financial metrics as they assist in determining the ability to generate cash from operations. Investors should be cautioned that EBITDA and Adjusted EBITDA should not be construed as an alternative to net earnings or cash flows as determined under IFRS. The reconciling items between net earnings, EBITDA, and Adjusted EBITDA are as follows:

	Three months ended										Six months ended
(in thousands)	June 30,					$			%		June 30,					$			%
		2022			2021	Change			Change			2022			2021	Change			Change
Net Profit	$	111		$	2,977	$	(2,866	)	-96.3	%	$	1,692		$	6,692	$	(5,000	)	-74.7	%
Interest Expense		111			29		82		282.8	%		360			57		303		531.6	%
Income Tax Expense		283			129		154		119.4	%		979			189		790		418.0	%
Depreciation and Amortization		426			353		73		20.7	%		831			707		124		17.5	%
EBITDA	$	931		$	3,488	$	(2,557	)	-73.3	%	$	3,862		$	7,645	$	(3,783	)	-49.5	%

Other Income		(263	)		–		(263	)	100.0	%		(263	)		–		(263	)	0.0	%
Adjusted EBITDA	$	668		$	3,488	$	(2,820	)	-80.8	%	$	3,599		$	7,645	$	(4,046	)	-52.9	%

Irwin Naturals Unaudited Condensed Combined Consolidated Interim Statements of Financial Position

		June 30,			December 31,
	Notes		2022			2021
ASSETS
Current Assets:
Cash		$	999		$	625
Other Financial Assets			–			1
Trade Receivables	15		13,942			16,394
Inventory	6		21,488			18,652
Prepaid Expenses and Other Current Assets	5		1,364			1,469
Total Current Assets			37,793			37,141

Non-Current Assets:
Property and Equipment	7		183			190
Right-of-Use Assets	9		4,291			3,722
Notes Receivable from IN Nevada Shareholders	18		4,182			3,264
Notes Receivable from Related Parties	11		155			–
Goodwill	4		14,211			–
Intangible Assets	11		87			87
Other Non-Current Assets			242			165
Deferred Tax Asset	20		2,641			2,650
Total Non-Current Assets			25,992			10,078

TOTAL ASSETS		$	63,785		$	47,219

LIABILITIES
Current Liabilities:
Trade and Other Payables	10	$	12,097		$	13,310
Reserve for Returns			491			814
Lease Liability – Current	9		1,878			1,366
Note Payable – Current	14		31			–
Line of Credit	8		9,047			6,178
Total Current Liabilities			23,544			21,668

Non-Current Liabilities:
Lease Liability – Non Current	9		2,483			2,434
Note Payable – Non Current	14		507			–
Contingent Consideration	4		7,450			–
Deferred Tax Liability	20		47			1
TOTAL LIABILITIES			34,031			24,103

EQUITY
Subordinate Voting Shares	12		3,002			3,000
Proportionate Voting Shares	12		4,945			–
Multiple Voting Shares	12		59			59
Class B Non Voting Shares	12		13,751			13,750
Accumulated Other Comprehensive Income			(12	)		(11	)
Retained Earnings			1,529			189
Total Controlling Interest			23,274			16,987
Non-Controlling Interest of IN Nevada	19		6,480			6,129
Total Equity			29,754			23,116
TOTAL LIABILITIES & EQUITY		$	63,785		$	47,219

Irwin Naturals Unaudited Condensed Combined Consolidated Interim Statements of Profit and Comprehensive Income

	For the Three Months Ended						For the Six Months Ended
	June 30,			June 30,			June 30,			June 30,
		2022			2021			2022			2021
Operating Revenue	$	21,809		$	26,593		$	44,403		$	50,728
Cost of Sales		(12,250	)		(14,487	)		(23,798	)		(26,875	)
Gross Profit		9,559			12,106			20,605			23,853

Operating Expenses:
Selling, General and Administrative Expenses		9,054			8,971			17,574			16,915
Gain on Sale of Property and Equipment		–			–			–			–
Income from Operations		505			3,135			3,031			6,938

Other Expense:
Interest Income		–			–			–			–
Interest Expense		(111	)		(29	)		(360	)		(57	)
Listing Expense		–			–			–			–
Gain / (Loss) on Foreign Currency Exchange		–			–			–			–
Total Other Income / (Expense)		(111	)		(29	)		(360	)		(57	)

Profit before Income Taxes		394			3,106			2,671			6,881

Income Tax Expense (Note 20)		(283	)		(129	)		(979	)		(189	)

Net Profit		111			2,977			1,692			6,692
Less: Net Profit Attributable to
Non-Controlling Interest of IN Nevada		(72	)		–			(351	)		–
Net Profit Attributable to Controlling Interest	$	39		$	2,977		$	1,341		$	6,692

Foreign Currency Translation Differences		(12	)		–			(8	)		–

Total Comprehensive Income		99			2,977			1,684			6,692
Less: Comprehensive Income Attributable to
Non-Controlling Interest of IN Nevada		(72	)		–			(351	)		–
Comprehensive Income Attributable to Controlling Interest	$	27		$	2,977		$	1,333		$	6,692

Earnings per share – basic	$	0.09		$	2.83		$	1.41		$	6.52
Earnings per share – diluted	$	0.00		$	2.83		$	0.01		$	6.52
Weighted average number of shares outstanding – basic		1,200,309			1,052,632			1,200,156			1,026,181
Weighted average number of shares outstanding – diluted		322,460,549			1,052,632			321,917,412			1,026,181

Irwin Naturals Unaudited Condensed Combined Consolidated Interim Statements of Cash Flows

	For the Six Months Ended
	June 30,			June 30,
		2022			2021

Net Profit	$	1,692		$	6,692
Adjustments to Reconcile Net Profit to Net Cash Provided by Operating Activities:
Depreciation and Amortization		831			707
Change in Allowance for Doubtful Accounts		37			114
Change in Inventory Reserve		(1,154	)		–
Deferred Tax Asset		56			–
Non-Cash Share Capital from Acquisitions		4,946			–
Interest Expense		361			57
Income Taxes Expense		979			189
Changes in Working Capital:
Trade Receivables		2,372			(372	)
Inventory		(1,682	)		(332	)
Prepaid Expenses and Other Assets		26			413
Trade and Other Payables		(2,119	)		3,077
Reserve for Returns		(323	)		(7	)
Changes in Other Non-Current Assets		(77	)		(29	)
Net Cash Provided by Operating Activities		5,945			10,509

Cash Flow from Investing Activities:
Disposal of Property and Equipment		(48	)		–
Contingent Consideration		7,450			–
Goodwill		(14,211	)		–
Net Cash Used in Investing Activities		(6,809	)		–

Cash Flow from Financing Activities:
Proceeds from Line of Credit		47,726			8,810
Payments on Line of Credit		(44,857	)		(12,352	)
Notes Receivable from Related Parties		(1,072	)		–
Distributions to Shareholders		–			(6,589	)
Payments on Lease Liability		(558	)		(653	)
Net Cash Used in Financing Activities		1,239			(10,784	)
Effect of Foreign Exchange on Cash		(1	)		–
Net Increase in Cash		374			(275	)
Cash at Beginning of the Period		625			442
Cash at End of the Period	$	999		$	167

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.